Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology… Read More »Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
Four presentations at oral and ePoster sessions focus on the effect of SNF472 in vascular calcification disorders Palma, Spain and San Diego, USA, October 22,… Read More »Sanifit Presents New Data for SNF472 in Treatment of Vascular Calcification at ASN Kidney Week 2020
SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused… Read More »SNF472 Mechanism of Action data published in British Journal of Pharmacology